- Home
- VHCP vs PROF Comparison
VHCP vs PROF Comparison
Compare VHCP & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VHCP | PROF |
|---|---|---|
| Founded | 2025 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.7M | 263.8M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | VHCP | PROF |
|---|---|---|
| Price | $10.00 | $7.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 38.5K | ★ 118.2K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | N/A | $92.40 |
| Revenue Next Year | N/A | $64.10 |
| P/E Ratio | ★ N/A | $38.32 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $9.89 | $3.92 |
| 52 Week High | $10.05 | $8.95 |
Technical Indicators
Market Signals| Indicator | VHCP | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 51.35 | 52.22 |
| Support Level | $9.97 | $7.00 |
| Resistance Level | $10.03 | $7.93 |
| Average True Range (ATR) | 0.01 | 0.38 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 50.00 | 40.26 |
Price Performance
Historical ComparisonAbout VHCP Vine Hill Capital Investment Corp. II Class A Ordinary Shares
Vine Hill Capital Investment Corp II is a blank check company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.